New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The campaign aims to increase awareness about Tuberculosis as a curable disease and promote early diagnosis.
Subscribe To Our Newsletter & Stay Updated
